BioCorRx to Participate in the First Annual Orange County Recovery Collaborative Resource Fair

ANAHEIM, CA, April 13, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company), a developer and provider of advanced solutions in the treatment of alcohol and opioid addition, today announced that the Company will participate in the first annual Orange County Recovery Collaborative (OCRC) resource fair on Saturday, April 14th. 

BioCorRx is a member of OCRC, which is designed to eliminate barriers and connect resources to those suffering from substance abuse. The resource fair will address prevention, education, resources, and services. There will be booths, guest speakers, workshops, and education sessions throughout the day. Assessments will be available for those seeking services.

Brady Granier, CEO, President, and Director, stated, “We are very proud be a member of OCRC and to support its important mission in the community. This is an important event for Orange County as it’s the first of its kind with many agencies coming together for one common purpose, which is to combat addiction. We encourage anyone who is suffering or has a loved one suffering from addiction to stop by for this free resource fair.”

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304

Primary Logo

Source: BioCorRx Inc